Sofinnova Crossover II
Public fund record: capital, investment focus and sources.
Growth fund based in Paris, managed by Sofinnova Partners. €725m reported at final close (source published November 2026).
Late-stage life sciences crossover fund backing clinical-stage biopharma and medtech companies, about 15 companies, primarily in Europe.
Fund details
- Final Close
- €725m
- Paris, France
- Growth
- Health & Bio
- Primarily Europe, selective investments in the US and other markets
- November 2026